Vantive
Vantive is a vital-organ therapy company focused on kidney care and broader organ support. The company develops dialysis and acute organ-support therapies, digital health platforms for remote monitoring and ICU care, and advanced services including clinician education and training. Vantive is investing in R&D and manufacturing capacity to expand digitally-enabled therapies, home-dialysis access, and clinical evidence generation.
Industries
Nr. of Employees
small (1-50)
Vantive
1 Baxter Parkway, Deerfield, IL USA 60015
Products
Dialysis and acute organ-support systems
Medical devices and systems for peritoneal dialysis, hemodialysis, expanded hemodialysis and continuous renal replacement therapy used in home, clinic and ICU settings.
Connected care and remote-monitoring platform for home therapy
Cloud-connected platform that receives automated peritoneal dialysis treatment data and provides clinicians a secure interface to monitor and act on patient data remotely.
Dialysis and acute organ-support systems
Medical devices and systems for peritoneal dialysis, hemodialysis, expanded hemodialysis and continuous renal replacement therapy used in home, clinic and ICU settings.
Connected care and remote-monitoring platform for home therapy
Cloud-connected platform that receives automated peritoneal dialysis treatment data and provides clinicians a secure interface to monitor and act on patient data remotely.
Services
Operational remote-monitoring service that transmits home therapy data to clinician teams to support adherence, clinical review and remote intervention.
Integration of real-time device telemetry and analytics into ICU workflows to support CRRT management and multi-organ support.
On-demand educational programs and immersive VR training for clinicians to learn device operation and acute-therapy procedures without reducing frontline service capacity.
Telephone and field support for renal and acute devices, spare parts ordering, hardware swap and recovery services.
Operational remote-monitoring service that transmits home therapy data to clinician teams to support adherence, clinical review and remote intervention.
Integration of real-time device telemetry and analytics into ICU workflows to support CRRT management and multi-organ support.
On-demand educational programs and immersive VR training for clinicians to learn device operation and acute-therapy procedures without reducing frontline service capacity.
Telephone and field support for renal and acute devices, spare parts ordering, hardware swap and recovery services.
Expertise Areas
- Dialysis and renal replacement therapies
- Home dialysis program implementation
- Continuous renal replacement therapy (CRRT) in ICU
- Remote patient monitoring and digital health
Key Technologies
- Peritoneal dialysis (PD) systems
- Automated peritoneal dialysis (APD) remote monitoring
- Hemodialysis and expanded hemodialysis (HDx)
- Continuous renal replacement therapy (CRRT)
News & Updates
Five-year global investment program to expand R&D and manufacturing capacity and accelerate digitally-enabled therapies and services for kidney and vital-organ support.
Perspective on leveraging technology, partnerships and digital health to improve access to home dialysis and reach underserved populations.
Summary and commentary on a large multi-hospital analysis linking higher CRRT utilization to improved ICU patient survival.
Public announcement of plans to invest more than US $1 billion over five years to expand research and development and production capacity for digitally-enabled therapies and services.
Five-year global investment program to expand R&D and manufacturing capacity and accelerate digitally-enabled therapies and services for kidney and vital-organ support.
Perspective on leveraging technology, partnerships and digital health to improve access to home dialysis and reach underserved populations.
Summary and commentary on a large multi-hospital analysis linking higher CRRT utilization to improved ICU patient survival.
Public announcement of plans to invest more than US $1 billion over five years to expand research and development and production capacity for digitally-enabled therapies and services.